Lu L, Leemhuis T, Srour E F, Yang Y C
Department of Medicine (Hematology/Oncology), Indiana University School of Medicine, Indianapolis.
Exp Hematol. 1992 May;20(4):418-24.
The cDNA encoding human interleukin (IL)-9 has recently been cloned and the recombinant molecule found to enhance erythroid colony formation in vitro by bone marrow, peripheral blood, and cord blood cells. In our present report, recombinant human (rhu) IL-9 was evaluated, alone and in combination with other cytokines, for its effect on colony formation by erythroid progenitor (erythroid burst-forming units, BFU-E) and precursor (erythroid colony-forming units, CFU-E) cells in low density (LD), nonadherent LD density T-lymphocyte-depleted (NALT-), and immunofluorescence-sorted CD34+++DR+ and CD34+++DR+CD33- cells from normal human bone marrow. When highly enriched CD34+++DR+ and CD34+++DR+CD33- cells were plated at 200 and 100 cells/ml in the presence of 5% (vol/vol) 5637-cell-conditioned medium and erythropoietin (Epo) under serum-containing conditions, 46 and 51 day-14 BFU-E were observed, respectively. The enhancing effect of rhuIL-9 was similar to that of 5637 CM on colony formation by Epo-dependent BFU-E and CFU-E in these enriched sorted CD34+++DR+ and CD34+++DR+CD33- cells under serum-containing and serum-depleted culture conditions. No significant synergistic or additive effect of rhuIL-9 was noted when used in conjunction with rhu interleukin 3 (rhuIL-3), rhu interleukin 6 (rhuIL-6), and/or rhu granulocyte-macrophage colony-stimulating factor (rhuGM-CSF) under the same culture conditions. The cloning enhancing effect elicited by human IL-9 is Epo dependent, although IL-9 alone sustains the survival of erythroid progenitor cells in vitro, as assessed by delayed additions of Epo to the cultures. The ability of human IL-9 to stimulate BFU-E and CFU-E colony formation using low numbers of highly enriched progenitor cells in serum-depleted conditions demonstrates the direct effect of IL-9 on erythroid progenitors and implicates its potential role in the enhancement of erythropoiesis.
编码人白细胞介素（IL）-9的互补DNA（cDNA）最近已被克隆出来，并且发现重组分子可增强骨髓、外周血和脐血细胞在体外形成红系集落的能力。在我们目前的报告中，对重组人（rhu）IL-9单独以及与其他细胞因子联合使用时，对低密度（LD）、非贴壁低密度T淋巴细胞去除（NALT-）以及从正常人骨髓中通过免疫荧光分选得到的CD34+++DR+和CD34+++DR+CD33-细胞中的红系祖细胞（红系爆式集落形成单位，BFU-E）和前体细胞（红系集落形成单位，CFU-E）形成集落的影响进行了评估。当在含血清条件下，将高度富集的CD34+++DR+和CD34+++DR+CD33-细胞以200和100个细胞/毫升的密度接种于含有5%（体积/体积）5637细胞条件培养基和促红细胞生成素（Epo）的培养基中时，分别观察到46个和51个第14天的BFU-E。在含血清和无血清培养条件下，rhuIL-9对依赖Epo的BFU-E和CFU-E在这些富集分选的CD34+++DR+和CD34+++DR+CD33-细胞中形成集落的增强作用与5637条件培养基相似。在相同培养条件下，当rhuIL-9与rhu白细胞介素3（rhuIL-3）、rhu白细胞介素6（rhuIL-6）和/或rhu粒细胞-巨噬细胞集落刺激因子（rhuGM-CSF）联合使用时，未观察到明显的协同或相加作用。人IL-9引发的集落增强作用依赖于Epo，尽管单独的IL-9可维持红系祖细胞在体外的存活，这通过向培养物中延迟添加Epo来评估。人IL-9在无血清条件下使用少量高度富集的祖细胞刺激BFU-E和CFU-E集落形成的能力证明了IL-9对红系祖细胞的直接作用，并暗示了其在增强红细胞生成中的潜在作用。
